bluebird bio (BLUE) AML Case is Unlikely Driven By Lentiglobin, Here's Why - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $45.00 price target on bluebird bio (NASDAQ: BLUE) after management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
